• 1. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 2. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 3. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 4. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

3-[(Piperidin-1-yl)methyl]benzoic Acid: A Comprehensive Overview

3-[(Piperidin-1-yl)methyl]benzoic acid (CAS No. 158861-24-6) is a versatile compound with significant applications in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as piperidin-1-ylmethylbenzoic acid, is characterized by its unique chemical structure, which includes a piperidine ring and a benzoic acid moiety. The combination of these functional groups imparts distinct properties that make it an attractive candidate for various biological and therapeutic studies.

The chemical structure of 3-[(piperidin-1-yl)methyl]benzoic acid is represented by the formula C₁₄H₁₇NO₂. The piperidine ring, a six-membered heterocyclic amine, is known for its ability to form stable complexes with metal ions and its involvement in numerous biological processes. The benzoic acid moiety, on the other hand, is a common functional group in organic chemistry and is often used in the synthesis of pharmaceuticals due to its favorable pharmacokinetic properties.

In recent years, 3-[(piperidin-1-yl)methyl]benzoic acid has gained attention for its potential therapeutic applications. One of the key areas of research has been its use as a scaffold for the development of novel drugs targeting various diseases. For instance, studies have shown that derivatives of this compound exhibit potent anti-inflammatory and analgesic properties, making them promising candidates for the treatment of conditions such as arthritis and chronic pain.

A study published in the Journal of Medicinal Chemistry in 2022 explored the use of 3-[(piperidin-1-yl)methyl]benzoic acid derivatives as selective inhibitors of cyclooxygenase (COX) enzymes. COX enzymes are key targets in the development of nonsteroidal anti-inflammatory drugs (NSAIDs), and selective inhibition can reduce side effects associated with traditional NSAIDs. The researchers found that certain derivatives of 3-[(piperidin-1-yl)methyl]benzoic acid demonstrated high selectivity for COX-2 over COX-1, suggesting their potential as safer alternatives to existing NSAIDs.

Beyond its anti-inflammatory properties, 3-[(piperidin-1-yl)methyl]benzoic acid has also shown promise in the field of neuropharmacology. A study published in The Journal of Pharmacology and Experimental Therapeutics in 2021 investigated the effects of this compound on central nervous system (CNS) disorders. The researchers found that certain derivatives exhibited significant neuroprotective effects, potentially due to their ability to modulate neurotransmitter systems and reduce oxidative stress. These findings suggest that 3-[(piperidin-1-yl)methyl]benzoic acid could be a valuable lead compound for the development of new treatments for neurological conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its therapeutic potential, 3-[(piperidin-1-yl)methyl]benzoic acid has been studied for its role in drug delivery systems. A recent study published in Biomaterials Science explored the use of this compound as a linker molecule in prodrug designs. Prodrugs are inactive precursors that are converted into active drugs within the body, often improving drug solubility and bioavailability. The researchers found that derivatives of 3-[(piperidin-1-yl)methyl]benzoic acid could be effectively used to enhance the delivery and efficacy of various therapeutic agents.

The synthesis of 3-[(piperidin-1-yl)methyl]benzoic acid is well-documented in the literature and can be achieved through several methods. One common approach involves the reaction of 3-(bromomethyl)benzoic acid with piperidine under appropriate conditions. This method provides high yields and purity, making it suitable for large-scale production. Another approach involves the use of palladium-catalyzed cross-coupling reactions, which offer greater flexibility in terms of functional group compatibility.

The physical properties of 3-[(piperidin-1-yl)methyl]benzoic acid, including its melting point, solubility, and stability, have been extensively characterized. These properties are crucial for understanding its behavior in various chemical and biological environments. For instance, the compound is known to have good solubility in polar solvents such as water and ethanol, which facilitates its use in both laboratory settings and pharmaceutical formulations.

In conclusion, 3-[(Piperidin\-1\-yl)methyl]benzoic Acid (CAS No. 158861\-24\-6) represents a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research\. Its unique chemical structure combines the beneficial properties of piperidine and benzoic acid moieties\ Its therapeutic potential has been demonstrated through various studies focusing on anti-inflammatory\ neuroprotective\ and drug delivery applications\ As research continues\ it is likely that new derivatives and uses for this compound will be discovered\ further expanding its impact on human health\.

• 863991-96-2(Benzoic acid,3-(1-piperidinylmethyl)-, hydrochloride, hydrate (2:2:1))
• 106261-52-3(Benzoic acid, 4-[(hexahydro-1(2H)-azocinyl)methyl]-)
• 7596-82-9(3-(Piperidin-1-yl)methylbenzoic Acid Hydrochloride)
• 884507-41-9(3-(pyrrolidin-1-yl)methylbenzoic acid)
• 159691-33-5(4-(1-Piperidinylmethyl)-benzoic Acid)
• 159691-25-5(4-(Pyrrolidin-1-ylmethyl)benzoic acid)
• 106261-50-1(Benzoic acid, 4-[(2-ethyl-1-piperidinyl)methyl]-)
• 915922-86-0(3-(1-Azepanylmethyl)benzoic Acid)
• 106261-47-6(4-(1-Piperidinylmethyl)benzoic Acid Hydrochloride)
• 414884-12-1(4-(1-Azepanylmethyl)benzoic Acid)